May 19, 2005FDA Antiviral Drugs Advisory Committee Meeting 1 Tipranavir NDA 21-814 Drug Interactions Yuanchao (Derek) Zhang, Ph.D. Clinical Pharmacology.

Slides:

Advertisements

Similar presentations

Non-Steroidal Anti-Inflammatory Drugs

Advertisements

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

Antiretroviral Combinations James A Zachary MD LSU Health Sciences Center HIV Outpatient Clinic December 13, 2004

FDA Pharmacogenetic Labels A Clinical Perspective David A Flockhart MD, PhD Indiana University School of Medicine Clinical Pharmacology Subcommittee of.

Drug interactions.

Updated Guidelines for Managing HIV/HCV Co-Infection John J Faragon, PharmD, BCPS, AAHIV-P Regional Pharmacy Director, NY/NJ AIDS Education and Training.

American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.

Drug Interactions Scott R. Penzak, Pharm.D. Pharmacokineticist

The link between non-clinical and clinical testing ~ are non-clinical tests predictive of clinical effects? C Mike Perkins MD Pfizer Global Research &

Gastrointestinal Drugs Advisory Committee Meeting March 6, 2003 Drug Interactions of Aprepitant Venkat Jarugula, Ph.D. Clinical Pharmacology and Biopharmaceutics.

Clinically Significant Drug Interactions

Clinical Pharmacology Overview From the Antiviral Perspective Kellie Schoolar Reynolds, Pharm.D. Pharmacokinetics Team Leader Office of Clinical Pharmacology.

Chapter 6 Drug Interactions 1.

Drug Interactions Scott R. Penzak, Pharm.D. Pharmacokineticist

Background: Focus on P-gp Questions:

CYP2C8 and Drug Interactions

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Pharmacokinetics: Bioavailability Asmah Nasser, M.D.

INTERPATIENT VARIABILITY OF DRUG DISPOSITION & DOSAGE ADJUSTMENT

Pharmacokinetics (PK): What the body does to the drug? Most drugs: Enter the body by crossing barriers Distributed by the blood to the site of action Biotransform.

Virtual Drug Development in Southern California, A Pre-Clinical Focus in vitro tests to support IND submissions David Johnson, Ph.D. Director, DMPK MicroConstants,

Toxicity Interactions In Anagrams InfectionsPregnancy.

Drug Interactions Cara L. Alfaro, Pharm.D. Clinical Reviewer Division of Neuropharmacological Drug Products Food and Drug Administration This presentation.

1 To Use Them Together or Not Understanding Drug Interactions With HCV Medications Rajwant Minhas, FH Resident HIV/AIDS Rotation May 2012.

ZOLPIDEM Dr Anne-Louise Swain Clinical Forensic Medical Officer

Clinical Aspects of Treatment with Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.

1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.

Pharmacogenetics & Pharmacogenomics Personalized Medicine.

Issues and Challenges in the Evaluation and Labeling of Drug Interaction Potentials of NME Shiew-Mei Huang, Ph.D. Deputy Office Director for Science Office.

Tamoxifen, Endoxifen, and CYP2D6 Sally Usdin Yasuda, MS, PharmD Senior Reviewer, Division of Clinical Pharmacology 1 Office of Clinical Pharmacology Center.

EFFECTS OF DULOXETINE ON THE PHARMACOKINETICS OF NEBIVOLOL IN HEALTHY VOLUNTEERS Corina Briciu 1, Maria Neag 2, Dana Muntean 3, Corina Bocsan 2, Anca Buzoianu.

GS-9350: A Pharmacoenhancer Without anti-HIV Activity AA Mathias, P German, M Lee, C Callebaut, L Xu, L Tsai, B Murray, H Liu, K Yale, D Warren and BP.

PHAR 751 Pharmacogenomics

The effect of fluvoxamine on the pharmacokinetics, and safety of ivabradine in healthy subjects Adina Popa 1, Laurian Vlase 2, Maria Neag 3, Dana Muntean.

PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,

Sprout Pharmaceuticals Inc. FDA Approval Date: August 18, 2015

Phase I Issues for Novel TB Drugs Dakshina M. Chilukuri, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics, FDA OPEN FORUM ON KEY ISSUES IN TB.

Drug Interactions Phase III May Drug Interactions If two drugs when given together change the effects of each other it is called Drug Interaction.

1 Systemic Human Exposure of Pimecrolimus and Tacrolimus Following Topical Application Tapash K. Ghosh, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics.

Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.

Shirley M. Tsunoda Liver Transplant, Drug Metabolism/PK Research Interests Investigating the genetic and environmental factors that influence variability.

Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs) M Shelton, S Ford, M Anderson, S Murray, J Ng-Cashin XVI.

Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,

Simultaneous evaluation of the activity of five cytochrome P450 enzymes by a cocktail study in healthy volunteers Department of Pharmacy Practice & Sciences.

Clarifications of Lecture #36- Drug Interactions I

DRUG INTERACTIONS I Lecture #36. Drug Interactions Terms Therapeutic Drug Interaction ADR Additive Synergism.

Metabolic Stability Lee, Sang-Hwi. -2- Overview Metabolism is the enzymatic modification of compounds to increase clearance. It is a determinant.

Drugs acting via ion channels and transporters Prof. M. Kršiak Department of Pharmacology, Third Faculty of Medicine Ruská 87, Prague 10, Subject: General.

1 Transporters and Their Role in Drug Interactions.

1 Drug-Drug Interaction Concept Paper: Issues Related to CYP/Transporter- and Induction-Based Interactions and Multiple- Inhibitor Drug Interaction Studies:

1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.

DDIs with new DAAs Franco Maggiolo AO Papa Giovanni XXIII Bergamo.

Drug interactions in dementia Stephen Bleakley Locality Lead Pharmacist November 2010

Clinicaloptions.com/hepatitis Effect of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus Slideset on: Garg V, van Heeswijk R, Lee JE,

Drug X S-warfarin Agents that DECREASE metabolism (inhibit or compete for cytochrome P450) are more important than those that increase metabolism.

Eucrisa™ - Crisaborole

Pharmacology Tutoring – Factors Affecting Drug Action

Introduction of Biopharmaceutics & Pharmacokinetics

Toxicology Drug Poisioning.

Pharmacokinetics.

Enzymes and drugs P450 enzymes breakdown/metabolize active drug

Drug Metabolism Drugs are most often eliminated by biotransformation and/or excretion into the urine or bile. The process of metabolism transforms lipophilic.

Pharmacokinetics.

Understanding the Basics of Pharmacology

Senior Medical Director, Cardiovascular

Pharmacokinetics and Drug Interactions in the new HCV Clinical Management SOC.

Basic principles of DDIs with ARVs: an introduction

Non-competitive antagonism

Dose adjustments in patients with CKD are based on the change in the concentration-time profile for the drug of interest. Dose adjustments in patients.

Presentation transcript:

May 19, 2005FDA Antiviral Drugs Advisory Committee Meeting 1 Tipranavir NDA Drug Interactions Yuanchao (Derek) Zhang, Ph.D. Clinical Pharmacology Reviewer Office of Clinical Pharmacology and Biopharmaceutics CDER, FDA

2 Outline Potential for TPV/r to alter concentrations of other drugs Potential for other drugs to alter TPV/r concentrations Examples of unknown drug interactions Question for the Antiviral Drugs Advisory Committee

3 Potential for TPV/r to alter concentrations of other drugs In vitro drug metabolism (effect of TPV) –TPV is a CYP3A inducer and inhibitor. –TPV is an inhibitor of CYP1A2, CYP2C9, CYP2C19, and CYP2D6. In vivo net effect of TPV/r (500/200 bid) –Inhibition of CYP3A –Potential net effect of TPV/r on CYP2D6 is inhibition (RTV inhibits CYP2D6). –Net effect of TPV/r on CYP1A2, CYP2C9 and CYP2C19 is not known (RTV may induce CYP1A2 and CYP2C9).

4 Potential for TPV/r to alter concentrations of other drugs In vivo effect on P-gp transporter –TPV is a P-gp inducer. –Net effect of TPV/r is P-gp induction. –Data supporting this conclusion Loperamide interaction study Clarithromycin interaction study Protease inhibiter interaction data Multiple-dose TPV/r PK study with 14 C-TPV

5 Potential for TPV/r to affect other drugs Summary Inhibition of CYP3A- Administration of TPV/r can increase plasma concentrations of drugs metabolized by CYP3A. In vitro TPV and RTV inhibit CYP2D6- TPV/r likely inhibit CYP2D6 (may increase concentrations of drugs metabolized by CYP2D6). Effect on CYP1A2, CYP2C9 and CYP2C19 is not known. Induction of P-gp- Administration of TPV/r can decrease plasma concentrations of P-gp substrates. Effect on dual CYP3A and P-gp substrates- It depends…

6 Potential for TPV/r to alter concentrations of other drugs Competing effects of TPV/r on CYP3A and P-gp make prediction of in vivo drug interactions difficult –Expect concentrations of CYP3A substrates to increase –Expect concentrations of P-gp substrates to decrease

7 Potential for TPV/r to affect CYP3A and P-gp dual substrate drugs Net effect will vary depending on the relative affinity of the co-administered drugs for CYP3A and P-gp and the extent of intestinal first-pass metabolism/efflux –CYP3A seems to be dominant for atorvastatin absorption (Atorvastatin concentrations increase to 5-9 fold). –P-gp seems to be dominant for absorption of other RTV- boosted protease inhibitors (Amprenavir concentrations decrease 50%, lopinavir concentrations decrease 50-70%, saquinavir concentrations decrease 80%).

8 Potential for other drugs to alter TPV/r TPV is a CYP3A substrate. TPV is a P-gp substrate.

9 Potential for other drugs to alter TPV/r Summary Co-administration of TPV/r and drugs that induce CYP3A and/or P-gp may decrease TPV plasma concentrations.

10 Potential for other drugs to alter TPV/r Summary Co-administration of TPV/r and drugs that inhibit CYP3A may not further increase TPV plasma concentrations. –This conclusion is supported by results of a multiple- dose TPV/r PK study with 14 C-labeled TPV.

11 Potential for other drugs to alter TPV/r Summary Co-administration of TPV/r and drugs that inhibit P-gp may increase TPV plasma concentrations. –TPV/r + fluconazole increased TPV concentrations –TPV/r + clarithromycin increased TPV concentrations

12 Examples of unknown drug interactions 1.Anticoagulant (warfarin) –TPV/r may increase or decrease warfarin concentrations (competing effects on CYP2C9). 2.Calcium channel blockers –Cannot predict effect of TPV/r (competing effects on CYP3A and P-gp) 3.Anti-diabetic agents –The effect of TPV/r on CYP2C8, which metabolizes most glitazones, is not known. –Sulfonylureas are metabolized by CYP2C9, interaction is possible.

13 Question for the Antiviral Drugs Advisory Committee Current information indicates the net effect of TPV/r on substrates of CYP1A2, CYP2C9, CYP2C19 and CYP2D6 is not known, and there are competing effects of TPV/r on CYP3A (inhibition) and P-glycoprotein (induction). What additional drug interaction information is important for the safe use of TPV/r in the target population?